# Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

> **NCT00577850** · PHASE1 · COMPLETED · sponsor: **Warner Chilcott** · enrollment: 32 (actual)

## Conditions studied

- Osteopenia
- Osteoporosis

## Interventions

- **DRUG:** risedronate
- **DRUG:** alendronate

## Key facts

- **NCT ID:** NCT00577850
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577850, "Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00577850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*